H.I.G.-WHITEHORSE-EUROPE
30.5.2024 12:01:34 CEST | Business Wire | Press release
H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G."), is pleased to announce that it has co-arranged a new €450 million financing package for Astek (the “Company” or the “Group”).
Founded in 1988 and controlled by its founder Jean-Luc Bernard, Astek is a global player in engineering and technology consulting. Headquartered in Boulogne-Billancourt, France, Astek operates in more than 20 countries with 8400 employees. Led by Julien Gavaldon since 2013, the Group has experienced significant growth as a result of organic activity and ten strategic acquisitions, over the past four years. The Group has developed leading market positions in its key geographies, notably in France, Poland, and Canada, in addition to growing positions in Northern and Western Europe, the Middle East, and Asia.
In 2021, H.I.G. WhiteHorse Europe acted as the sole arranger of a €170 million financing package used to refinance the Group’s existing loans and provide additional capital for growth. Having reached its business goals two years ahead of schedule, Astek is further strengthening its financial resources to support its plans of continued growth through a new senior-secured financing package of €450 million co-arranged by H.I.G. Additionally, Astek has welcomed its long-term investor, Intermediate Capital Group (“ICG”), as a strategic partner. ICG has provided an additional €110 million in equity financing to the Group.
Jean-Luc Bernard, Founder and Chairman of the Supervisory Board of Astek, said: “H.I.G. has been our partner since 2021 and I would like to thank them for their renewed confidence. The trust that has been built with H.I.G. has further strengthened the Group and Astek is now well-positioned for continued growth and profitability.”
Julien Gavaldon, Chief Executive Officer of Astek, said: “Thanks to our partnership with H.I.G., we have had a very successful growth trajectory, reaching our objectives two years ahead of schedule. We are determined to continue growing the Group, with the goal of exceeding 1 billion euros of turnover before 2027. H.I.G.’s renewed confidence in Astek, coupled with our new strategic partnership with ICG, positions us among the global leaders in digital transformation and technology consulting.”
Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said: “Astek is a remarkable company, led by a high-quality management team, and we are grateful for their renewed trust in H.I.G. WhiteHorse Europe. We are excited to continue supporting Jean-Luc Bernard, Julien Gavaldon, and Astek’s 8,400 employees as they embark on this exciting new phase of development.”
Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We deeply appreciate the renewed confidence shown by Jean-Luc Bernard and Julien Gavaldon in H.I.G. WhiteHorse Europe. Over the past years, Astek has achieved remarkable and consistent growth, establishing itself as a prominent global player. Its impressive market share gains, driven by approximately 20% organic growth (significantly exceeding market expansion) and a well-managed buy-and-build strategy, are a testimony to its success. We are delighted to continue supporting Astek as it embarks on this new chapter of development.”
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $62 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
- H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.
Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
* Based on total capital raised by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530188790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
